Organon & Co
 
公司簡況
財務
派息紀錄
盈利預測
股權變動
ETF簡況
 
 
 
公司概覽
業務類別 Drug Manufacturers - General
業務概覽 Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
公司地址 30 Hudson Street, Floor 33, Jersey City, NJ, USA, 07302
電話號碼 +1 551 430-6900
傳真號碼 --
公司網頁 https://www.organon.com
員工數量 10000
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Mr. Daniel Karp Executive Vice President, Corporate Development -- 25/04/2025
Ms. Lynette Holzbaur Senior Vice President, Finance and Corporate Controller -- 24/02/2026
Mr. Matthew M. Walsh Executive Vice President, Chief Financial Officer and Principal Accounting Officer 美元 900.00K 24/02/2026
Mr. Vittorio Nisita Executive Vice President and Head of Enterprise Services and Solutions -- 25/04/2025
Mr. Joseph T. Morrissey, Jr Interim Chief Executive Officer, Executive Vice President and Head of Manufacturing and Supply 美元 750.00K 24/02/2026
Mr. Kirke Weaver Executive Vice President, General Counsel and Corporate Secretary -- 25/04/2025
Ms. Kathryn DiMarco Senior Vice President and Corporate Controller -- 28/02/2025
Mr. Aaron Falcione Executive Vice President and Chief Human Resources Officer -- 25/04/2025
Ms. Rachel A. Stahler Executive Vice President and Chief Digital and Growth Officer -- 25/04/2025
Dr. Juan Camilo Arjona Ferreira, M.D. Executive Vice President, Head of Research and Development and Chief Medical Officer 美元 650.00K 25/04/2025
 
董事會成員
董事會 職務 更新日期
Dr. Helene D. Gayle, M.D. Independent Director 24/02/2026
Ms. Shalini Sharp Independent Director 24/02/2026
Mr. Robert A. Essner Lead Independent Director 24/02/2026
Ms. Rochelle B. Lazarus Independent Director 24/02/2026
Ms. Ramona A. Sequeira Director 24/02/2026
Ms. Carrie S. Cox Executive Chairman of the Board 24/02/2026
Dr. Philip Ozuah, M.D.,PhD Independent Director 24/02/2026
Ms. Deborah R. Leone Independent Director 24/02/2026
Dr. Alan Ezekowitz, M.D.,PhD Independent Director 24/02/2026
Ms. Grace Puma Whiteford Independent Director 24/02/2026
Ms. Cynthia M. Patton Independent Director 24/02/2026
 
所屬ETF (更新日期: 07/03/2026 02:57)
代號 名稱 佔比% ▼ 持有日期
AVKAdvent Convertible & Income Fund<0.000001%31/07/2025
BBMCJPMorgan BetaBuilders US Mid Cap Eq ETF<0.000001%22/12/2025
BKSEBNY Mellon US Small Cap Core Equity ETF<0.000001%05/02/2026
BTALAGF U.S. Market Neutral Anti-Beta<0.000001%01/12/2025
CDEICalvert US Large-Cp Div, Eq AndIncETF<0.000001%23/06/2025
COWZPacer US Cash Cows 100 ETF<0.000001%27/02/2026
CSDInvesco S&P Spin-Off ETF<0.000001%23/06/2025
CVLCCalvert US Large-Cp Cor Rspnb ETF<0.000001%23/06/2025
CVMCCalvert US Mid-Cp Cor Rspnb ETF<0.000001%23/06/2025
CVYInvesco Zacks Multi-Asset Income ETF<0.000001%04/06/2025
DCORDimensional US Core Equity 1 ETF<0.000001%18/11/2025
DEUSXtrackers Russell US Multifactor ETF<0.000001%30/06/2025
DEWWisdomTree Global High Dividend ETF<0.000001%16/10/2025
DHSWisdomTree US High Dividend ETF<0.000001%11/12/2025
DIVGlobal X SuperDividend™ US ETF<0.000001%02/09/2025
DIVBiShares Core Dividend ETF<0.000001%28/02/2026
DTDWisdomTree US Total Dividend ETF<0.000001%11/12/2025
EODAllspring Global Dividend Opportunity<0.000001%31/05/2025
EZMWisdomTree U.S. MidCap Earnings ETF<0.000001%11/12/2025
FEACFidelity Enhanced U.S. All-Cap Eq ETF<0.000001%08/12/2025
  1    2    3    4    5   6    7    8  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.